{"first_name":"David","last_name":"Brand","permalink":"david-brand","crunchbase_url":"http://www.crunchbase.com/person/david-brand","homepage_url":null,"birthplace":null,"twitter_username":null,"blog_url":null,"blog_feed_url":null,"affiliation_name":"Unaffiliated","born_year":null,"born_month":null,"born_day":null,"tag_list":null,"alias_list":null,"created_at":"Fri Mar 16 13:44:22 UTC 2012","updated_at":"Fri Mar 16 13:46:19 UTC 2012","overview":"<p>Mr. David Brand has more than three decades of pharmaceutical industry experience.  Prior to Tarsa, he served as CEO and president of Cardiokine, where he led strategic and organizational development and negotiated a significant global agreement with Biogen Idec for late stage development and marketing of lixivaptan.  Previously, Mr. Brand spent over 30 years at GlaxoSmithKline and its predecessor companies.  Most recently, he headed the U.S. GI/CNS, product development, metabolic and cardiovascular business units, leading the U.S. launches of Paxil®, Requip® and Avandia®, the pre-launch development of Coreg®, Kytril® and Augmentin® ES/XR, and many co-marketing and licensing deals.  Earlier, Mr. Brand held international senior management positions in marketing, acquisitions, business development and regional country management.  He currently serves on the board of directors at Intekrin Therapeutics.  Mr. Brand holds a bachelor of commerce degree from Concordia University in Montreal.</p>","image":null,"degrees":[],"relationships":[{"is_past":false,"title":"President, Founder & Chief Executive Officer, Director","firm":{"name":"Tarsa Therapeutics","permalink":"tarsa-therapeutics","type_of_entity":"company","image":{"available_sizes":[[[150,80],"assets/images/resized/0007/4051/74051v1-max-150x150.jpg"],[[250,134],"assets/images/resized/0007/4051/74051v1-max-250x250.jpg"],[[345,186],"assets/images/resized/0007/4051/74051v1-max-450x450.jpg"]],"attribution":null}}}],"investments":[],"milestones":[],"video_embeds":[],"external_links":[],"web_presences":[]}